SOX18 Targeting as a Potential, Viable Therapeutic Avenue for Kaposi Sarcoma-Reply

Affiliations

Comment

Rafael Salido-Vallejo et al. JAMA Dermatol. 2022.

. 2022 Dec 1;158(12):1459-1460.

doi: 10.1001/jamadermatol.2022.4332.

¹ Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain.

No abstract available

Comment on

Treatment With Oral Propranolol for Refractory Classic Cutaneous Kaposi Sarcoma.
Salido-Vallejo R, González-Menchen A, Alcántara-Reifs C, España A. Salido-Vallejo R, et al. JAMA Dermatol. 2022 Jul 1;158(7):832-834. doi: 10.1001/jamadermatol.2022.1278. JAMA Dermatol. 2022. PMID: 35544086 No abstract available.
SOX18 Targeting as a Potential, Viable Therapeutic Avenue for Kaposi Sarcoma.
Ojala PM, Francoís M. Ojala PM, et al. JAMA Dermatol. 2022 Dec 1;158(12):1458-1459. doi: 10.1001/jamadermatol.2022.4341. JAMA Dermatol. 2022. PMID: 36223085 No abstract available.